AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,377,733 | +117.7% | 126,092 | +101.0% | 0.01% | +166.7% |
| Q2 2023 | $2,929,611 | +32.0% | 62,746 | +8.1% | 0.00% | 0.0% |
| Q1 2023 | $2,219,922 | -22.7% | 58,022 | +10.7% | 0.00% | -25.0% |
| Q4 2022 | $2,872,726 | +404.0% | 52,422 | +174.1% | 0.00% | +300.0% |
| Q3 2022 | $570,000 | +7.3% | 19,122 | -23.8% | 0.00% | – |
| Q4 2021 | $531,000 | -5.3% | 25,102 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $561,000 | +4.3% | 25,102 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $538,000 | -26.1% | 25,102 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $728,000 | +43.9% | 25,102 | +28.0% | 0.00% | 0.0% |
| Q4 2020 | $506,000 | +5.4% | 19,605 | +25.6% | 0.00% | 0.0% |
| Q3 2020 | $480,000 | +121.2% | 15,605 | +78.9% | 0.00% | – |
| Q2 2020 | $217,000 | -5.2% | 8,722 | -15.5% | 0.00% | – |
| Q4 2019 | $229,000 | -2.6% | 10,322 | 0.0% | 0.00% | – |
| Q3 2019 | $235,000 | – | 10,322 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $125,180,178 | 50.58% |
| COMMODORE CAPITAL LP | 790,000 | $30,225,400 | 4.60% |
| Redmile Group, LLC | 2,044,389 | $78,218,323 | 3.39% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 202,561 | $7,749,984 | 3.20% |
| Ghost Tree Capital, LLC | 275,000 | $10,522,000 | 3.11% |
| Avidity Partners Management LP | 2,447,000 | $93,622,220 | 3.11% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $22,736,043 | 3.08% |
| Logos Global Management LP | 400,000 | $15,304,000 | 2.19% |
| Yiheng Capital Management, L.P. | 1,125,791 | $43,072,764 | 1.70% |
| Boxer Capital, LLC | 831,495 | $31,813 | 1.56% |